Table 1.

Measures taken at each assessment

	Eligibility Assessment	Weekly trial assessments
		0	1	2	3	4	5	6	7	8	9	10	11	12
Demographics, drug use history, CIDI (methamphetamine dependence), MINI (depression, psychotic disorders and mania), DIP (family history of psychotic disorders), RCQ, BCIS, BIS items, SAPAS	x
Saliva samples			x	x	x	x	x	x	x	x	x	x	x	x
TLFB for days of methamphetamine use	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Days of other substance use	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Adverse events			x	x	x	x	x	x	x	x	x	x	x	x
Concomitant medications		x	x	x	x	x	x	x	x	x	x	x	x	x
Concomitant treatment		x	x	x	x	x	x	x	x	x	x	x	x	x
SDS		x	x	x	x	x	x	x	x	x	x	x	x	x
CEQ		x	x	x	x	x	x	x	x	x	x	x	x	x
AWQ		x	x	x	x	x	x	x	x	x	x	x	x	x
BPRS items		x	x	x	x	x	x	x	x	x	x	x	x	x
WPAI-GH		x	x	x	x	x	x	x	x	x	x	x	x	x
EQ-5D-5L		x	x	x	x	x	x	x	x	x	x	x	x	x
Health service use and criminal justice involvement		x	x	x	x	x	x	x	x	x	x	x	x	x
TSQM						x				x				x

CIDI Composite International Diagnostic Interview, MINI Mini International Neuropsychiatric Interview, DIP Diagnostic Interview for Psychosis, RCQ Readiness to Change Questionnaire, BCIS Beck Cognitive Insight Scale, BIS Birchwood Insight Scale, SAPAS Standardised Assessment of Personality – Abbreviated Scale, TLFB timeline followback, SDS Severity of Dependence Scale, CEQ Craving Experience Questionnaire, AWQ Amphetamine Withdrawal Questionnaire, BPRS Brief Psychiatric Rating Scale, WPAI-GH Work Productivity and Activity Impairment Questionnaire – General Health V2, EQ-5D-5L Five-dimension five-level version of EuroQol questionnaire, TSQM Treatment Satisfaction Questionnaire – Medication